Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 10;63(2):116-130.
doi: 10.5114/reum/195012. eCollection 2025.

Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective

Affiliations
Review

Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective

Julia Domańska-Poboża et al. Reumatologia. .

Abstract

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by joint inflammation, degradation of cartilage and bone, and potential systemic effects. This paper provides a comprehensive historical overview of RA treatment, tracing the evolution from ancient empirical methods to modern targeted therapies. Advancements in the understanding of RA's immunopathology have led to the development of conventional, biological, and targeted disease-modifying antirheumatic drugs, including tumor necrosis factor α inhibitors and Janus kinase inhibitors. These innovations have been pivotal in transforming RA management, allowing for more personalized and effective treatment strategies. The historical progression in RA treatment reflects a shift from symptomatic management to targeted interventions aimed at the underlying mechanisms of the disease. This shift has not only improved clinical outcomes but also enhanced the quality of life for those affected by RA, underscoring the importance of ongoing research and adaptation of therapeutic strategies.

Keywords: JAK inhibitor; biologic DMARD; conventional synthetic DMARD; methotrexate; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sparks JA. Rheumatoid Arthritis. Ann Intern Med 2019; 170: ITC1–ITC16, DOI: 10.7326/AITC201901010. - DOI - PubMed
    1. Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 2019; 6: 164–173, DOI: 10.1016/S2215-0366(18)30255-4. - DOI - PubMed
    1. Landré-Beauvais AJ. The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Joint Bone Spine 2001; 68: 130–143, DOI: 10.1016/s1297-319x(00)00247-5. - DOI - PubMed
    1. Burns CM. The History of Cortisone Discovery and Development. Rheum Dis Clin North Am 2016; 42: 1–14, vii, DOI: 10.1016/j.rdc.2015.08.001. - DOI - PubMed
    1. Benedek TG. History of the development of corticosteroid therapy. Clin Exp Rheumatol 2011; 29 (5 Suppl 68): S5–S12. - PubMed

LinkOut - more resources